Our analysis revealed a positive correlation between AGO2 expression and adverse clinical outcomes in ACC, including poorer survival, higher Weiss scores, and advanced tumor stages, emphasizing its potential as a biomarker. Here, AGO2 is linked to adrenal cortex carcinoma.